Toronto, Canada

Melissa Beilschmidt

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Boehringer Ingelheim Io Canada Inc.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Melissa Beilschmidt: Innovator in Antibody Research

Introduction

Melissa Beilschmidt is a prominent inventor based in Toronto, Canada. She has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody therapies. Her work is characterized by a commitment to advancing medical science and improving patient outcomes.

Latest Patents

Melissa holds a patent for "FLT3 Agonist Antibodies and Uses Thereof." This patent represents her innovative approach to targeting specific pathways in cancer treatment, showcasing her expertise in antibody research. She has successfully secured 1 patent that highlights her contributions to the field.

Career Highlights

Melissa is currently employed at Boehringer Ingelheim (Canada) Inc., where she continues to push the boundaries of scientific research. Her role at the company allows her to collaborate with other talented professionals in the industry, further enhancing her impact on biotechnology.

Collaborations

Throughout her career, Melissa has worked alongside notable colleagues such as Arif Jetha and Phil Gobeil. These collaborations have fostered a dynamic environment for innovation and have contributed to the success of their projects.

Conclusion

Melissa Beilschmidt is a dedicated inventor whose work in antibody research is paving the way for new therapeutic options. Her contributions to the field are invaluable, and her ongoing efforts promise to make a lasting impact on medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…